CREIGHTON UNIVERSITY

Ensysce Biosciences Pioneers Novel Opioids with Built-in Overdose Prevention Technology

3 months ago

• Ensysce Biosciences has developed chemically modified oxycodone that remains inactive unless taken orally, significantly reducing abuse potential while maintaining pain relief efficacy. • The innovative technology includes built-in overdose protection mechanisms that prevent drug release when excessive doses are taken, addressing a critical safety concern in pain management. • The FDA has granted both Fast Track and Breakthrough Therapy designations to Ensysce's modified oxycodone, recognizing the urgent medical need for safer opioid alternatives.

rTMS Shows Promise in Treating OCD, Especially in Patients with Comorbid Depression

7 months ago

• A meta-analysis of 25 RCTs indicates that repetitive transcranial magnetic stimulation (rTMS) has a moderate therapeutic effect on obsessive-compulsive disorder (OCD) severity. • rTMS demonstrates a significant treatment response compared to sham conditions, with an average response rate of 39.5% versus 8.8%, respectively. • Greater improvement in depression severity, longer TMS sessions, and fewer TMS sessions are associated with greater improvement in OCD severity. • Clinicians should consider rTMS for OCD, particularly in patients who have not responded to other treatments or those with comorbid depression.